ArticleLeukemia2014
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.Journal for immunotherapy of cancer · 2023Trial
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.Nature medicine · 2021Trial
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Arginase-1-specific T cells target and modulate tumor-associated macrophages.Journal for immunotherapy of cancer · 2025Article
- Regulatory Mechanisms of Co-Inhibitory Receptors in Tuberculosis Immunity: Implications for Therapeutic Targets.ImmunoTargets and therapy · 2025Review
- Tumor microenvironment antigens.Seminars in immunopathology · 2023Review
- An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.Frontiers in immunology · 2023Article
- A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice.Vaccines · 2022Article
- Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.Cancers · 2021Article
- An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.Oncoimmunology · 2021Article
- Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.Frontiers in immunology · 2020Article
- Article
- Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.Cancer immunology, immunotherapy : CII · 2019Review
- Anti-regulatory T cells are natural regulatory effector T cells.Cell stress · 2019Article
- Inflammation induced PD-L1-specific T cells.Cell stress · 2019Article
- Cancer immune therapy for myeloid malignancies: present and future.Seminars in immunopathology · 2019Review
- The T-win® technology: immune-modulating vaccines.Seminars in immunopathology · 2019Review
- Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.Frontiers in immunology · 2018Review
- Anti-regulatory T cells.Seminars in immunopathology · 2017Review
- Malignant Mesothelioma Effusions Are Infiltrated by CD3Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24091833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.